TY  - GEN
AU  - Matulonis,Ursula A
AU  - Berlin,Suzanne
AU  - Ivy,Percy
AU  - Tyburski,Karin
AU  - Krasner,Carolyn
AU  - Zarwan,Corrine
AU  - Berkenblit,Anna
AU  - Campos,Susana
AU  - Horowitz,Neil
AU  - Cannistra,Stephen A
AU  - Lee,Hang
AU  - Lee,Julie
AU  - Roche,Maria
AU  - Hill,Margaret
AU  - Whalen,Christin
AU  - Sullivan,Laura
AU  - Tran,Chau
AU  - Humphreys,Benjamin D
AU  - Penson,Richard T
TI  - Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
SN  - 1527-7755
PY  - 2010///0105
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Fallopian Tube Neoplasms
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neoplasms, Glandular and Epithelial
KW  - Ovarian Neoplasms
KW  - Peritoneal Neoplasms
KW  - Prognosis
KW  - Quinazolines
KW  - administration & dosage
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - antagonists & inhibitors
KW  - Risk Assessment
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2009.23.2777
ER  -